Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328359 | Acta Haematologica Polonica | 2013 | 5 Pages |
Abstract
Median time on treatment was 9.2 months; 53% of patients remain on therapy. Median PFS was 13.9 months and DOR has not yet been reached. Responses increased with longer treatment: comparing to previous data described at ASH 2011, the CR rate increased from 16% to 39%, and the ORR increased from 69% to 75%.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Wojciech Jurczak, Simon Rule, Peter Martin, Rebecca Auer, Brad S. Kahl, Agnieszka Giza, Bożena Jachimczak, Ranjana H. Advani, Jorge Romaguera, Michael Williams, Jacqueline Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Jesse McGreivy,